Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged
27/04/2026 07:13
April 27 (Reuters) - GSK plc GSK.L: GSK PLC - TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION GSK PLC - TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION GSK - TESARO'S REMAINING CLAIM FOR DECLARATORY JUDGMENT AGAINST ANAPTYSBIO UNCHANGED GSK - ANAPTYSBIO SEEKS TO REVOKE TESARO'S LICENCE FOR DOSTARLIMAB GSK: GSK AND TESARO FIRMLY OF VIEW THAT ALLEGATIONS ARE ENTIRELY WITHOUT MERIT AND REMAIN FOCUSED ON PURSUING THAT CLAIM AT TRIAL Source text: ID:nRSa9962Ba Further company coverage: GSK.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged